REG - Celadon Pharma. PLC - Change of Name

Celadon PharmaceuticalsAnnouncement

29/03/2022 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220329:nRSc3693Ga&default-theme=true

RNS Number : 3693G  Celadon Pharmaceuticals PLC  29 March 2022

29 March 2022

 

Celadon Pharmaceuticals Plc

 

("Celadon" or the "Company")

 

Change of name

 

Further to yesterday's announcement, the Company confirms that, the change of
name from Summerway Capital plc to Celadon Pharmaceuticals Plc, is effective
on the London Stock Exchange as of today.

 

As a result, the Company's stock market ticker is now CEL and its ISIN and
SEDOL remain unchanged. The change of name will not affect any rights of
shareholders and existing share certificates should be retained as they will
remain valid and no new share certificates will be issued.

 

Enquiries:

 

 Celadon Pharmaceuticals Plc
 Mo Noonan                                                 078 764 44977

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Andrew Potts / Patrick Dolaghan                            020 7523 800

 

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company targeting the
research, cultivation, manufacturing and supply of cannabinoid-based
medicines. Its primary focus is on improving quality of life for chronic pain
sufferers, as well as exploring the potential of cannabinoid-based medicines
for other conditions such as autism. Its UK facility comprises a laboratory
designed to meet UK-GMP standards, and capacity for a large indoor hydroponic
growing facility that has received a Home Office Licence to legally grow high
THC medicinal cannabis for the purpose of producing test batches of cannabis
oil to support its application to the MHRA. The Company's subsidiary, LVL,
owns a MHRA conditionally approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CANSEMSMUEESEID